Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results
Rhea-AI Summary
Nevro Corp. (NYSE: NVRO) reported its Q4 and full-year 2024 financial results, highlighting a pending acquisition by Globus Medical for $250 million ($5.85 per share) expected to close in Q2 2025. The company's Q4 2024 worldwide revenue decreased 9.1% to $105.5 million, with U.S. revenue declining 9.9% to $91.4 million.
Key Q4 metrics include: gross profit of $65.9 million (62.5% margin), net loss from operations of $51.4 million, and adjusted EBITDA of negative $5.2 million. For full-year 2024, worldwide revenue decreased 3.9% to $408.5 million, with gross profit at $269.5 million (66.0% margin).
Notable developments include the launch of HFX iQ™ with HFX AdaptivAI™ platform in November 2024 and its European expansion in January 2025. The company's cash position strengthened to $292.5 million as of December 31, 2024.
Positive
- Cash position increased by $15.5M to $292.5M in Q4
- Full-year 2024 adjusted EBITDA improved to -$13.6M from -$17.7M in 2023
- Operating expenses improved by $3.2M (3.4%) excluding one-time items
Negative
- Q4 revenue declined 9.1% to $105.5M
- Q4 gross margin decreased to 62.5% from 70.1% YoY
- Q4 net loss from operations widened to $51.4M from $11.8M YoY
- U.S. permanent implant procedures decreased 7.0% in Q4
- Full-year revenue declined 3.9% to $408.5M
News Market Reaction
On the day this news was published, NVRO gained 1.05%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
"We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free patients from the burden of chronic pain."
Fourth-Quarter 2024 Business Highlights and Recent Developments
- On February 6, 2025, Nevro and Globus Medical (NYSE: GMED) announced that they had entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction valued at approximately
$250 million $5.85 - Launched the full market release of HFX iQ™ with HFX AdaptivAI™, a responsive, personalized pain management platform powering the HFX iQ spinal cord stimulation (SCS) system in November 2024.
- Launched the HFX iQ SCS system in select European countries in January 2025 following receipt of CE Mark Certification in November 2024.
- As previously announced on October 29, 2024, new data was published in the Journal of Pain Research demonstrating significant, durable pain relief and long-term and clinically meaningful reductions in hemoglobin A1c (HbA1c) and weight in study participants with painful diabetic neuropathy and Type 2 diabetes who received 10 kHz high-frequency SCS therapy.
- As previously announced on November 18, 2024, new data was published in Medical Devices: Evidence and Research which demonstrate the superiority of the Nevro1™ SI Joint Fusion System, a posterior-integrated transfixation cage system offering enhanced stability, minimized bone removal and increased fusion potential compared to a posterolateral cylindrical-threaded single implant system.
Fourth-Quarter 2024 Financial Results
Worldwide revenue for the fourth quarter of 2024 was
International revenue in the fourth quarter of 2024 was
Gross profit for the fourth quarter of 2024 was
Operating expenses for the fourth quarter of 2024 were
Net loss from operations for the fourth quarter of 2024 was
Adjusted EBITDA for the fourth quarter of 2024 was negative
Cash, cash equivalents and short-term investments totaled
Full-Year 2024 Financial Results
Nevro's full-year 2024 worldwide revenue was
International revenue was
Gross profit for full-year 2024 was
Net loss from operations for full-year 2024 was
For more information regarding the non-GAAP financial measures discussed in this press release, please see the financial table at the end of this release for GAAP to non-GAAP reconciliations, definitions and further information regarding the use of non-GAAP metrics.
2025 Financial Guidance and Fourth-Quarter 2024 Earnings Conference Call and Webcast
As previously announced on February 6, 2025, given the pending acquisition of Nevro by Globus Medical, Nevro is not issuing full-year 2025 guidance, nor is the company holding an earnings conference call and webcast in connection with reporting its fourth-quarter and full-year 2024 financial results.
Internet Posting of Information
Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The Company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.
About Nevro Corp.
Headquartered in
Senza®, Senza II®, Senza Omnia®, and HFX iQ™ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy™. Nevro's unique support services provide every patient with HFX Coach™ support throughout their pain relief journey and every physician with HFX Cloud™ insights for enhanced patient and practice management.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp. Patents covering Senza HFX iQ and other Nevro products are listed at Nevro.com/patents.
To learn more about Nevro, visit www.nevro.com and connect with us on LinkedIn, X, Facebook, and Instagram.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding the consummation of the transaction described above. These forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from those indicated in such forward-looking statements, including but not limited to the ability of the parties to consummate the proposed transaction and the possibility that various closing conditions for the transaction may not be satisfied or waived, and the ability to realize the benefits expected from the transaction. The forward-looking statements in this communication are based on information available to Nevro as of the date hereof, and Nevro disclaims any obligation to update any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. For additional information regarding forward-looking statements, please refer to discussions under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in our most recent Annual Report on Form 10-K, and in our other reports filed with the Securities and Exchange Commission ("SEC"). Nevro's SEC filings are available on the Investor Relations section of its website at https://nevro.com/English/us/investors/overview/default.aspx and on the SEC's website at www.sec.gov.
The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements: (i) the proposed transaction may not be completed in a timely manner or at all, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect Nevro or the expected benefits of the proposed transaction or that the approval of Nevro's stockholders is not obtained; (ii) the failure to realize the anticipated benefits of the proposed transaction; (iii) the possibility that competing offers or acquisition proposals for Nevro will be made; (iv) the possibility that any or all of the various conditions to the consummation of the merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, including in circumstances which would require Nevro to pay a termination fee or other expenses; and (vi) the effect of the announcement or pendency of the merger on Nevro's ability to retain and hire key personnel, or its operating results and business generally.
No Offer or Solicitation
This press release is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.
Additional Information and Where to Find It
This press release may be deemed solicitation material in respect of the proposed transaction. A Nevro special stockholder meeting will be announced to obtain Nevro stockholder approval in connection with the proposed transaction. Nevro expects to file with the SEC a proxy statement and has filed or may file with the SEC other relevant documents in connection with the proposed transaction. Nevro stockholders are urged to read the definitive proxy statement and other relevant materials carefully and in their entirety when they become available because they will contain important information about Nevro and the proposed transaction. Investors may obtain a free copy of these materials (when they are available) and other documents filed by Nevro with the SEC at the SEC's website at www.sec.gov, and at Nevro's website at https://www.nevro.com.
Participants in the Solicitation
Nevro and its directors, executive officers and certain employees and other persons may be deemed to be participants in soliciting proxies from its stockholders in connection with the proposed transaction. Information regarding Nevro's directors and executive officers is set forth in Nevro's proxy statement on Schedule 14A for its 2024 Annual Meeting of Stockholders, which was filed with the SEC on April 12, 2024, and in Nevro's Current Reports on Form 8-K filed with the SEC. Additional information regarding the persons who may, under the rules of the SEC, be considered to be participants in the solicitation of Nevro's stockholders in connection with the proposed transaction and any direct or indirect interests they may have in the proposed transaction will be set forth in Nevro's definitive proxy statement for its special stockholder meeting to be filed with the SEC in connection with the proposed transaction.
Investor and Media Contact:
Angie McCabe
Vice President, Investor Relations & Corporate Communications
angeline.mccabe@nevro.com
Nevro Corp. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) | |||||||
Three Months Ended | Year Ended | ||||||
2024 | 2023 | 2024 | 2023 | ||||
(unaudited) | |||||||
Revenue | $ 105,548 | $ 116,176 | $ 408,518 | $ 425,174 | |||
Cost of revenue | 39,629 | 34,699 | 138,990 | 135,114 | |||
Gross profit | 65,919 | 81,477 | 269,528 | 290,060 | |||
Operating expenses | |||||||
Research and development | 11,987 | 12,420 | 51,511 | 54,418 | |||
Sales, general and administrative | 76,198 | 80,598 | 309,769 | 334,704 | |||
Amortization of intangibles | 737 | 246 | 2,948 | 246 | |||
Change in fair value of | (9,803) | — | (6,679) | — | |||
Impairment of goodwill | 38,208 | — | 38,208 | — | |||
Total operating expenses | 117,327 | 93,264 | 395,757 | 389,368 | |||
Loss from operations | (51,408) | (11,787) | (126,229) | (99,308) | |||
Other income (expense) | |||||||
Interest income (expense), net | (3,645) | 781 | (13,583) | 6,152 | |||
Change in fair market value of warrants | 1,385 | (8,051) | 27,887 | (8,051) | |||
Gain on extinguishment of debt | — | 3,934 | — | 3,934 | |||
Other income (expense), net | 727 | (436) | (421) | (586) | |||
Loss before income taxes | (52,941) | (15,559) | (112,346) | (97,859) | |||
Provision for income taxes | 169 | (6,578) | 1,093 | (5,646) | |||
Net loss | $ (53,110) | $ (8,981) | $ (113,439) | $ (92,213) | |||
Changes in foreign currency | (2,032) | 1,087 | (907) | 1,164 | |||
Changes in unrealized gains (losses) | (625) | 821 | (62) | 1,687 | |||
Net change in other comprehensive | (2,657) | 1,908 | (969) | 2,851 | |||
Comprehensive loss | $ (55,767) | $ (7,073) | $ (114,408) | $ (89,362) | |||
Net loss per share, basic and diluted | $ (1.41) | $ (0.25) | $ (3.06) | $ (2.56) | |||
Weighted average shares used to compute | 37,616,374 | 36,277,243 | 37,088,476 | 35,981,431 | |||
Nevro Corp. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) | |||
December 31, | December 31, | ||
Assets | |||
Current assets | |||
Cash and cash equivalents | $ 94,539 | $ 104,217 | |
Short-term investments | 197,995 | 218,506 | |
Accounts receivable, net | 71,884 | 79,377 | |
Inventories | 103,268 | 118,676 | |
Prepaid expenses and other current assets | 8,316 | 10,145 | |
Total current assets | 476,002 | 530,921 | |
Property and equipment, net | 26,562 | 24,568 | |
Operating lease assets | 21,186 | 8,944 | |
Goodwill | — | 38,164 | |
Intangible assets, net | 24,408 | 27,354 | |
Other assets | 5,171 | 5,156 | |
Restricted cash | 512 | 606 | |
Total assets | $ 553,841 | $ 635,713 | |
Liabilities and stockholders' equity | |||
Current liabilities | |||
Accounts payable | $ 24,457 | $ 22,520 | |
Accrued liabilities | 38,415 | 45,297 | |
Short-term debt | 37,972 | — | |
Contingent liabilities, current portion | 1,781 | 9,836 | |
Other current liabilities | 318 | 5,722 | |
Total current liabilities | 102,943 | 83,375 | |
Long-term debt | 187,666 | 211,471 | |
Long-term lease liabilities | 25,525 | 4,634 | |
Contingent liabilities, long-term | 3,633 | 12,257 | |
Warrant liability | 853 | 28,739 | |
Other long-term liabilities | 2,213 | 2,092 | |
Total liabilities | 322,833 | 342,568 | |
Stockholders' equity | |||
Common stock, | 38 | 36 | |
Additional paid-in capital | 1,045,031 | 992,762 | |
Accumulated other comprehensive income (loss) | (1,212) | (243) | |
Accumulated deficit | (812,849) | (699,410) | |
Total stockholders' equity | 231,008 | 293,145 | |
Total liabilities and stockholders' equity | $ 553,841 | $ 635,713 | |
Nevro Corp. | |||||||
The following table presents a reconciliation of GAAP net loss, as prepared in accordance with | |||||||
Reconciliation of actual results: | |||||||
Three Months Ended | Year Ended December 31, | ||||||
2024 | 2023 | 2024 | 2023 | ||||
(unaudited) | (unaudited) | ||||||
GAAP Net Loss | $ (53,110) | $ (8,981) | $ (113,439) | $ (92,213) | |||
Non-GAAP Adjustments: | |||||||
Interest (income) expense, net | 3,645 | (781) | 13,583 | (6,152) | |||
Provision for income taxes | 169 | (6,578) | 1,093 | (5,646) | |||
Depreciation and amortization | 2,019 | 1,869 | 7,994 | 6,885 | |||
Stock-based compensation expense | 12,506 | 15,533 | 48,936 | 58,782 | |||
Amortization of intangibles | 737 | 246 | 2,948 | 246 | |||
Change in fair value of contingent | (9,803) | — | (6,679) | — | |||
Impairment of goodwill | 38,208 | — | 38,208 | — | |||
Change in fair market value of warrants | (1,385) | 8,051 | (27,887) | 8,051 | |||
Gain on extinguishment of debt | — | (3,934) | — | (3,934) | |||
Litigation-related expenses | 1,062 | 2,941 | 4,114 | 15,913 | |||
Restructuring charges | 730 | — | 11,538 | 373 | |||
Supplier renegotiation charge | — | — | 6,000 | — | |||
Adjusted EBITDA | $ (5,222) | $ 8,366 | $ (13,591) | $ (17,695) | |||
Management uses certain non-GAAP financial measures, most specifically adjusted EBITDA, as a supplement to GAAP financial measures to further evaluate the Company's operating performance period over period, analyze the underlying business trends, assess performance relative to competitors and establish operational objectives.
Management believes it is important to provide investors with the same non-GAAP metrics it uses to evaluate the performance and underlying trends of the Company's business operations to facilitate comparisons to its historical operating results and evaluate the effectiveness of its operating strategies. Disclosure of these non-GAAP financial measures also facilitates comparisons of the Company's underlying operating performance with other companies in the industry that also supplement their GAAP results with non-GAAP financial measures.
EBITDA is a non-GAAP financial measure, which is calculated by adding interest income and expense, net; provision for income taxes; and depreciation and amortization to net loss. In calculating non-GAAP adjusted EBITDA, the Company further adjusts for the following items:
- Stock-based compensation expense and other equity-related charges – Nevro excludes non-cash costs related to the company's stock-based plans, which include stock options, restricted stock units and performance-based restricted stock units as these expenses do not require cash settlement from the company. In the period ended December 31, 2023, Nevro also excluded one-time equity-related charges of
$1.9 million - Amortization of intangibles – The company excludes amortization of intangibles from the acquisition of businesses.
- Change in fair value of contingent consideration – The company excludes the changes in the fair value of its contingent consideration liability.
- Goodwill impairment – The company excludes any goodwill impairment.
- Change in fair market value of warrants – The company excludes the changes in the fair value of its warrant liability.
- Gain on extinguishment of debt – The company excludes gains and losses from extinguishment of early debt repayment.
- Litigation-related expenses – The company excludes legal and professional fees as well as charges and credits associated with certain legal matters, which management considers not related to the underlying operating performance of the business.
- Restructuring charges – The company excludes charges incurred as a direct result of restructuring programs, such as salaries and other compensation-related expenses.
- Supplier contract renegotiation charge - Nevro excludes one-time costs associated with the renegotiation of a supplier contract in 2024.
The non-GAAP financial measure should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP financial measures, as it is not prepared in accordance with
Amounts may not add due to rounding.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-reports-fourth-quarter-and-full-year-2024-financial-results-302392084.html
SOURCE Nevro Corp.
FAQ
What is the acquisition price offered by Globus Medical for Nevro (NVRO)?
How much did Nevro's (NVRO) Q4 2024 revenue decline compared to 2023?
What was Nevro's (NVRO) cash position at the end of 2024?
What were Nevro's (NVRO) full-year 2024 revenue results?
When did Nevro (NVRO) launch its HFX iQ platform in Europe?
